Victory Pharma, Inc.

None  Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  Maxwell Biosciences brings 3 new leaders aboard Maxwell Biosciences   Maxwell Biosciences has added three new senior executives to its team as it aims to shed its preclinical status.  Tony Verco, M.D., will step into the role of chief medical officer, leading the company as it looks to take its chronic rhinosinusitis biomimetic therapy into the clinic next year. Most recently, Verco owned Shelton Clinical Research Consultants, and has previously held leadership roles at Medwell Capital Corp., Endpoint Research and AstraZeneca.   Verco is an expert in first-in-human studies and will help the biotech focus on the FDA regulatory pathway, Maxwell founder and CEO Joshua McClure told Fierce Biotech.   The company has also brought on Beth Burnside, Ph.D., as SVP of R&D strategy, while Donald Treacy Jr., Ph.D., will serve as SVP of development operations. Both leaders are joining Maxwell from Shire Pharmaceuticals. In April, the biotech tapped Edward Rudnic, Ph.D., to serve as chief operating officer. Rudnic was the founder, chairman and CEO of MiddleBrook Pharmaceuticals, and, before that, head of U.S. R&D at Shire Pharmaceuticals.   The current team has been working together for decades, McClure said. “Shire better watch out—we’re coming for their team.” Release Everest taps new CEO weeks after Blanchard’s abrupt departure Everest Medicines Not even a month after Everest announced CEO Kerry Blanchard’s resignation, the Chinese drug developer has selected pharma veteran Rogers Yongqing Luo to lead the biotech. Luo previously served as Brii Biosciences' president and general manager for greater China as well as CEO of Brii’s TSB Therapeutics unit. There, he oversaw the registration and commercialization of the amubarvimab/romlusevimab combination, the first COVID-19 neutralizing antibody treatment in the country. Before that, Luo headed up Gilead’s operations in China. The CEO also has held leadership roles at Big Pharmas Roche and Novartis. Luo has replaced Blanchard, who abruptly departed Everest in late August after serving two years as CEO. Blanchard, who joined the biotech after a stint at Innovent Biologics and a 17-year run at Eli Lilly, took Everest public months after taking up the CEO post.  Luo will now guide Everest as it aims to secure Chinese approvals for Calliditas Therapeutics’ Nefecon, which is approved in the U.S. for lgA nephropathy, as well as Tetraphase Pharmaceuticals’ Xerava, which is approved in the U.S. and EU for complicated intra-abdominal infections. Everest secured the rights for both drugs in China in 2019 and 2018, respectively. Fierce Biotech Celgene, Acceleron alum Backstrom to fill Scholar Rock's CEO spot Scholar Rock Jay Backstrom, M.D., former executive vice president for R&D at Merck-acquired Acceleron Pharma, is set to take the reins as Scholar Rock’s president and CEO, effective Oct. 20.  Before Acceleron, Backstrom was the chief medical officer at Celgene up to its acquisition by Bristol Myers Squibb. Prior to Celgene, he served as the VP of global medical and safety at Pharmion Corporation. The news marks the beginning of the end of Nagesh Mahanthappa’s 13-month interim tenure. The Scholar Rock co-founder was thrust into the role when then-CEO Tony Kingsley departed in August 2021 after just one year on the job. Kingsley became the CEO of Stablix in February 2022.   Now, Backstrom will lead the biotech as it funnels resources to its phase 3 stage asset, apitegromab. The asset’s lead indication is in spinal muscular atrophy, though Scholar Rock is also assessing it in the preclinical stage as a potential treatment for myosin-related disorders. Fierce Biotech > AlivaMab Discovery Services has reappointed Larry Green as CEO, effective immediately. Green is the founding CEO and assumes the role from Justin Mika, who has served as CEO for more than two years. Green will continue in his role as CEO of Ablexis. Release > Alliance Pharma has expanded its executive team with the addition of four C-suite hires as the bioanalytical services company continues to grow. Among the hires is Jean Pierre Boutrand, who will serve as chief operating officer; Vito Saccente as chief commercial officer; Glenn Weber as chief financial officer; and Susan Woolley as chief people officer. Fierce Biotech > Jeffrey Finer, M.D., Ph.D., is transitioning from his role as Septerna’s interim CEO to lead as permanent CEO. The biotech co-founder is also a partner for Third Rock Ventures, which led Septerna’s $100 million series A financing this January. Release > Germany’s Neuway, looking to push delivery of mRNA and other biotherapeutics into the central nervous system (CNS) and beyond, has slotted Chief Operating Officer Oliver Ernst into the CEO seat. Separately, the company selected Thomas Christoph, Ph.D., to don the chief development officer mantle. Ernst, for his part, joined Neuway back in 2019, initially serving as chief operating officer and managing director. Ernst will oversee Neuway’s efforts to build a “new class” of biologics centered on the company’s proprietary Engineered Protein Capsules, which it claims can cross the blood-brain barrier to treat CNS disorders. Release > Current Biologics has summoned Tom Hochuli to lead the cell and gene therapy startup as chief executive officer. Hochuli joins from Vibalogics Holdings, where he served for two years in the captain’s seat. Prior to his Vibalogics stint, Hochuli held a leadership role at CDMO juggernaut Catalent, Current said in a release. Current is a joint venture between Cincinnati Children's and CTI Clinical Trial & Consulting Services. The Cincinnati Children's Translational Core Laboratory claims it’s been at the forefront of development, testing and manufacturing of biologics “for early phase clinical trials for more than 15 years.” Release  > Avid Bioservices has tapped Michael Alston Jr. to serve as VP of operations. Alston has been with the company since 2019, and most recently served as director of project engineering. Release > A regime change is afoot at Q32 Bio, where Jodie Morrison has been named board member and acting CEO, taking over from Michael Broxson. During his stint as CEO, Broxson helped the company advance two programs into the clinic. Morrison, for her part, is a venture partner at Atlus Venture and previously helmed the ship at Cadent Therapeutics until its sale to Novartis in 2020. Release > Neuroscience company Delix Therapeutics has appointed Eliseo Salinas, M.D., to head up R&D. He most recently served as head of R&D at Passage Bio and has held leadership roles at Acadia Pharmaceuticals, Shire Pharmaceuticals, Elan Pharmaceuticals and Wyeth. Release   > Zentalis Pharmaceuticals, angling to discover and deploy small-molecule drugs across “fundamental biological pathways” of cancer, has named Carrie Brownstein, M.D., chief medical officer. As an experienced oncologist and hematologist, Brownstein enters the Zentalis fold with more than two decades of medical and biopharma know-how, Zentalis said in a release. Brownstein previously held the same role at Cellectis, preceded by at Celgene. Release > American Gene Technologies has bumped up Barry Wells, M.D., into the position of head of business development. The promotion follows Wells’ entry into AGT’s investor relations team back in 2019. “I am excited to have Barry leading our investor relations and business development efforts,” said AGT’s CEO Jeff Galvin. Release > Viracta Therapeutics is ushering in a new leader with the appointment of Mark Rothera as president and CEO. At the same time, Viracta’s former helmsman Ivor Royston, M.D.  will stick around to chip in on the company’s board of directors, Viracta said in a release. Rothera, for his part, is a 30-year industry vet, most recently serving as president and CEO of Silence Therapeutics. Before taking the vow of Silence, Rothera was CEO of Orchard Therapeutics, where he helped raise the profile of the gene therapy player and led it to a more than $600 million fundraising round. Release   > Wheeler Bio has appointed Roger Lias, Ph.D., as president and chief operating officer. Lias most recently served as chief commercial officer at Vibalogics, which was acquired this year by Recipharm. He previously served as CEO at Avid Bioservices and Stelis Biopharma. 

Cecilia Jones When Cecilia Jones started at Genzyme , there was next to nothing in Kendall Square. “It was just us,” Jones said. “There wasn’t much to even go for lunch.” Jones would work in Cambridge, MA, for the next 17 years — spending seven at Genzyme and 10 at Biogen , where she would go on to hold a VP role in finance — as Kendall Square and Cambridge grew into a biotech hub. “It’s like night and day,” Jones said of the area now. On Monday, Jones will return to Cambridge as the CFO of Agios , following a two-year stint at LogicBio (located less than 10 miles outside Cambridge). Jones joins Agios as the biotech is going through a period of continuous churn. In late 2020, Agios announced it was selling off its entire cancer portfolio , including Tibsovo , an AML drug. Since then, it has pivoted to rare diseases, starting with Pyrukynd , a drug for pyruvate kinase deficiency, which got its first approval in February of this year . In May, amid a larger market downturn, Agios laid off some 50 employees , and then in July, its CSO Bruce Car departed. Soon after, Jackie Fouse handed the CEO seat to Brian Goff , as Fouse transitioned to board chair. When asked about the turnover at Agios, Jones said, “I asked them the same questions.” But for Jones, Agios’ new look as a rare disease biotech was an attracting factor. She first worked in rare diseases at Genzyme, where she said she developed her passion for the field. “To me, being part of an organization that has the potential to make this positive impact on people with rare and genetically-defined diseases is incredibly rewarding. Obviously I don’t discover drugs, I don’t work in the lab, but I support the groups that do that,” Jones said. On Goff coming on as CEO, Jones said, “That was actually one of the things that attracted me to the job too, is Brian has a lot of rare disease expertise and commercial experience with launching rare disease drugs, so I think he was a perfect fit to try to lead the company in the next phases.” Jones moved to the US in 2000 to get her MBA from Harvard Business School. After graduating, she decided to stay in the US and landed her first job at Genzyme. “I had no background in biotech and had never worked in pharma or anything like that,” Jones said. “It was a completely new challenge for me. And this was also 20 years ago — I feel like biotech has become much more popular and much more known.” “In Argentina,” Jones said, where she grew up, “definitely, biotech was very nascent, and nobody knew much about it.” But Jones has stayed with the Boston-area biotechs. “I question that every winter,” Jones joked. She then added, “I’ve stayed very loyal to Massachusetts. I still have my Argentina roots, and I do go back home every year, but it’s been 22 years now.” — Lei Lei Wu Jay Backstrom → Scholar Rock founder Nagesh Mahanthappa took it upon himself to fill in as CEO when Tony Kingsley ultimately left for Versant protein stabilization biotech Stablix . But he’ll soon roll out the welcome mat for new chief executive Jay Backstrom , the R&D chief at Acceleron before Merck ’s $11.5 billion M&A play last year. The ex- Celgene CMO and head of global regulatory affairs also adds to his collection of board appointments, which includes Autolus Therapeutics , Be Biopharma , Disc Medicine and Lava Therapeutics . When Backstrom gets settled on Oct. 20, Mahanthappa will relinquish his seat on the board of directors and become a strategic advisor. Rogers Yongqing Luo → Everest Medicines has quickly filled the CEO slot that Kerry Blanchard left vacant in late August. Rogers Yongqing Luo had spent the last two years as president and general manager for Greater China at Brii Biosciences , and he helped get eight drugs past the finish line as Everest partner Gilead ’s global VP and China general manager. In June, Everest celebrated its Trodelvy approval in China, and Gilead then shelled out $280 million upfront for rights to the drug in China and select countries in Asia. Ten days after the deal was made, Blanchard called it quits . Mark Rothera → Mark Rothera has resurfaced as president and CEO of San Diego cancer biotech Viracta Therapeutics . In February, Rothera stepped aside as chief executive of UK RNAi player Silence Therapeutics and left his CFO, Craig Tooman , in charge with little explanation, but our Max Gelman indicated that Tooman’s M&A credentials could’ve been a factor in his appointment. Silence has cycled through a number of CEOs in the last five years, from Ali Mortazavi to David Horn Solomon (now with Pharnext ) to Rothera’s appointment in September 2020 after his stint as CEO of Orchard Therapeutics . Viracta’s lead program, a combination of nanatinostat and valganciclovir ( nana-val ), is in a Phase II trial for relapsed/refractory Epstein-Barr virus-positive lymphoma. Abigail Jenkins → A new era has dawned at Gamida Cell , where Julian Adams is retiring and Abigail Jenkins has replaced him as president and CEO. Formerly the chief commercial and business officer at Lyndra Therapeutics , Jenkins was business unit head of vaccines at Emergent BioSolutions , exiting the Baltimore company just as things really started to go sideways with the production of J&J’ s Covid-19 jab. Gamida Cell’s decision day with the FDA on its cell therapy omidubicel is Jan. 30, 2023. Amber Tong has more on Adams’ retirement . Matthias Alder → Gain Therapeutics has promoted Matthias Alder to CEO, as Eric Richman concentrates on his duties as a board member and senior advisor. As we pointed out at the time, Alder came to the protein misfolding biotech almost a year ago as COO, moving on from his CBO post at Autolus . From 2014-17, he was EVP, business development & licensing, general counsel and corporate secretary for Sucampo Pharmaceuticals . Richman is a 12-year MedImmune vet who took over as Gain’s CEO in July 2020 and guided the Bethesda, MD biotech to its modest IPO in March 2021, but its stock $GANX has taken a beating ever since, an unsurprising turn of events in the current bear market. Jodie Morrison → There’s a changing of the guard at Q32 Bio , now teaming up with Horizon on the anti-IL-7Rα antibody ADX-914 : Atlas Venture partner Jodie Morrison has been named acting CEO as former Goldfinch Bio exec Michael Broxson walks out the door. Morrison — the former chief executive at Cadent Therapeutics until it was sold to Novartis — takes a seat on the board and she’ll also preside over Q32 Bio’s program for complement disorders, ADX-097 , which is in an early-stage trial. → One week removed from ex- Trillium chief Jan Skvarka ’s appointment to the board of directors, Zentalis has poached Carrie Brownstein from Cellectis , naming her CMO. While she was medical chief at Cellectis, Brownstein started her tenure inauspiciously when a patient death prompted a clinical hold of the French biotech’s off-the-shelf CAR-T drug for multiple myeloma, a study that would resume four months later. Brownstein, a former senior medical director at Roche and a Regeneron oncology vet, was VP of global clinical R&D during her three years at Celgene. Piyush Sharma → Alnylam has made a pair of appointments as it claims a win with patisiran in ATTR amyloidosis with cardiomyopathy. Piyush Sharma (chief ethics & compliance officer) is a Pfizer alum who was head of compliance at Alexion once it became part of the AstraZeneca universe. And Evan Lippman (Alnylam’s first chief corporate development and strategy officer) says goodbye to Alessandro Riva ’s crew at Intima Bioscience , where he was president and COO. During a four-year run with Takeda , Lippman served as SVP, head of corporate development, M&A and valuation. Eliseo Salinas → Eliseo Salinas ’ next landing spot is with Delix Therapeutics , the Boston neuro biotech that launched in 2019 and nabbed $70 million in Series A financing almost exactly a year ago. Salinas, who signed on as R&D chief at Delix, had the same title at Passage Bio and split the scene in the midst of a reorg in March that refocused the pipeline and shaved off 13% of the staff. (CEO Bruce Goldsmith would later step down.) In May 2021, Salinas took over as interim medical chief when Gary Romano resigned mere days after CFO Richard Morris also decided to pack his bags. Prior to his time at Passage Bio, Salinas was CSO at Shire and Acadia Pharmaceuticals . Lisa French → Pulled to the surface from the quicksand of bankruptcy and opioid litigation, Mallinckrodt has recruited Lisa French as chief commercial officer after last week’s FDA approval of terlipressin . French replaces Hugh O’Neill and comes from Merck spinoff Organon , where she was the US women’s health business unit lead. She had a nearly 30-year career with the pharma giant that concluded as associate VP, US marketing lead for the HPV franchise before her move to Organon. Branded as Terlivaz , terlipressin earned the OK for adults with hepatorenal syndrome, but it does come with a black box warning. Shulamit Ron-Bigger → Aktis Oncology is on easy street — first house down — following an $84 million raise in late August , and as the radiopharmaceuticals space continues to heat up, Matthew Roden ’s squad has installed Shulamit Ron-Bigger as COO. Leaving Big Pharma behind, Ron-Bigger had led strategy and operations for Bristol Myers Squibb ’s research and early development organization. Glenn Pauly → As Alzheon touts its Alzheimer’s drug ALZ-801 without any clinical data to show for it — and the Framingham, MA biotech has a penchant for patting itself on the back a bit too hard with the data it does gather — it’s enlisted Glenn Pauly as head of commercial. Pauly has familiarity with the space from his days at Biogen, where he was US western division general manager and VP in charge of commercialization for the ill-fated Alzheimer’s drug Aduhelm . After holding sales roles at Genentech from 2008-17, Pauly became AstraZeneca’s senior director, market access, respiratory biologics. Gemma Brown → AstraZeneca’s Covid-19 partner Vaccitech has elevated Gemma Brown to CFO after a year as the Oxford spinout’s head of financial reporting. Brown had previously held a number of roles, including senior manager at EY from 2012-21. Despite AstraZeneca’s clash with the EU on supply issues, and concerns over blood clots with the Covid-19 vaccine it co-invented, Vaccitech’s IPO exceeded nine figures in April 2021, but its stock $VACC is down more than 75% since its Nasdaq debut. Regarding the development of Vaxzevria , AstraZeneca CEO Pascal Soriot told the BBC in June, “I don’t think I would do anything differently from what we did.” Phillip Samayoa → Coming off a major letdown with its hemophilia A gene therapy in which shares were routed, Generation Bio has promoted Phillip Samayoa to chief strategy officer. When he was a principal at Atlas Venture from 2016-18, Samayoa co-founded Generation Bio and Dyne Therapeutics , joining Generation Bio’s team as senior director (and then VP) of strategy and portfolio development. After co-founding Codiak BioSciences during his time at Flagship Pioneering , Samayoa jumped over to Merck as director of MRL Ventures Fund . → To start this month, Ashleigh Palmer ’s Provention Bio took out a $125 million loan with Hercules Capital before the FDA reaches a verdict on the BLA resubmission for anti-CD3 type 1 diabetes drug teplizumab . This week the New Jersey biotech has lined up NIBR human resources vet Sarah O’Brien as chief people officer. The former head of HR in North America for Sobi , O’Brien had been chief people officer before with Relay Therapeutics and, since last year, Ardelyx . Provention is trying to get off the mat with teplizumab after receiving a CRL for the ex- Eli Lilly drug in July 2021. Cindy Cao → Cindy Cao has replaced Bill Tente as chief regulatory officer of Humacyte , although Tente will stick around at the Laura Niklason -led regenerative medicine shop as an executive advisor. She had led regulatory affairs and quality assurance at Ascentage Pharma since 2018, but Cao has plenty of Big Pharma experience from Sanofi , Novo Nordisk and Bristol Myers. One more quick note: Former Air Force Surgeon General Bruce Green has joined Humacyte’s board of directors. → Returning from a nearly two-year break that he described on his LinkedIn as, “Retired. Golfed. Shaved a few strokes off my handicap,” ex-Shire HR chief Peter Lasky is making all the clutch putts as chief people officer of Waltham, MA antibody biotech DynamiCure . Before he worked on his golf game, Lasky was SVP, human resources at Deciphera and the chief HR officer at Wave Life Sciences . Oliver Ernst → Neuway Pharma, which is working on new ways of delivering drugs to the brain, is ushering in some new changes to its exec team with the promotion of Oliver Ernst to CEO and the appointment of Thomas Christoph as chief development officer. Ernst joined Neuway in 2019 as COO and managing director — having formerly served in roles at Brainlab and BASF . Ernst takes over the reins from co-founder Heiko Manninga , who will continue to serve as CSO and managing director. Meanwhile, Christoph joins the German company from Gruenenthal , where he led pharmacology and preclinical development teams. Ruth Thieroff-Ekerdt → Aging-focused Cambrian BioPharma has pulled in Ruth Thieroff-Ekerdt as EVP of clinical development. Thieroff-Ekerdt formerly served as scientific advisor at Organon and acting CMO at Forendo . Her career also spans stints as CMO at Sojournix , Aptalis , Strongbridge and Kaleido , and R&D roles at Bayer . → Université Libre de Bruxelles spinoff NeuVasQ Biotechnologies has locked in Emmanuel Lacroix as CEO and company director. Lacroix hails from UCB Ventures , where he was founding VP and partner. Earlier in his career, Lacroix was with UCB and Cellectis. Beth Burnside → Austin, TX-based Maxwell Biosciences has brought aboard three new execs with the appointments of Tony Verco (CMO), Beth Burnside (SVP of R&D strategy), and Donald Treacy (SVP, development operations). Verco joins up with the team at Maxwell with experience from roles at Shelton Clinical Research Consultants , Medwell Capital , Endpoint Research and AstraZeneca. Meanwhile, Burnside has had gigs at Lowery Creek Consulting , QRxPharma , MiddleBrook Pharmaceuticals and Shire; while Treacy has served at Magothy Consulting Group (CEO), MiddleBrook Pharmaceuticals (SVP of development and manufacturing operations), and Shire (senior director of analytical sciences). Scott Chaplin → Berkeley Lights is bringing in some firepower with the appointment of Scott Chaplin as chief legal officer and corporate secretary. Chaplin joins from Shield AI , where he was chief legal and people officer. Prior to Shield, Chaplin was with Vista Outdoor , Alliant Techsystems and Stanley . → CDMO ViroCell has brought on Susan Nichols as CBO. Nichols currently has a seat on the board of the Alliance for Regenerative Medicine. Nichols brings experience from her time as an executive officer at Propel BioSciences and CEO of Falcon Therapeutics . Sek Kathiresan → Jason Coloma ’s Maze Therapeutics has reserved space for Verve Therapeutics CEO Sek Kathiresan on the board of directors. Verve’s Phase Ib trial is ongoing with its cardiovascular drug — a single base editor named VERVE-101 — and Kathiresan’s crew has teamed up with Vertex in a gene editing deal worth $60 million upfront. → Charles Baltic is succeeding Christine White as chair of MEI Pharma ’s board. A board member at the San Diego cancer biotech since 2011, Baltic had been a senior advisor with Needham & Company, where he was also managing director and co-head of healthcare banking. Eric Ende → Eric Ende will take over for Herbert Conrad as chairman of Matinas BioPharma on Oct. 1, although Conrad will stay on the board. Ende, an ex- Merrill Lynch biotech analyst, also sits on the boards of Avadel Pharmaceuticals and NeuBase Therapeutics . → One of the few biotechs willing to brave the Nasdaq elements with an IPO this year , PepGen has welcomed Habib Dable to the board of directors. This is the third time in as many months that the former Acceleron CEO has popped up in this part of Peer Review after board appointments at Blueprint Medicines and Albireo . Lauren Silvernail → Under the leadership of CEO Julie Eastland , Harpoon Therapeutics has elected ex- Revance CFO and CBO Lauren Silvernail to the board of directors. The Allergan vet just spent four years as CFO and EVP of corporate development at Evolus . → Winston Kung is headed to the board of directors at Merck’s T cell engager partner Janux Therapeutics . Kung is a Celgene vet who handles the roles of COO and CFO at p53 biotech PMV Pharma . → CNS-focused Pasithea Therapeutics has brought in ex- Biosense CEO Alfred Novak to the board of directors after Yassine Bendiabdallah ’s exit. Last week, Pasithea named Merit Cudkowicz to its scientific advisory board.

Sept. 20, 2022 12:00 UTC Industry-leading talent joins leadership team as company accelerates its CLAROMER™ drug platform Tony Verco, MD, MBA, appointed Chief Medical Officer Beth Burnside, PhD, appointed Senior Vice President of Research and Development Strategy Donald Treacy, Jr., PhD, appointed Senior Vice President, Development Operations AUSTIN, Texas--(BUSINESS WIRE)-- MaxWell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced the appointments of three senior executives: Tony Verco, MD, MBA, as Chief Medical Officer; Beth Burnside, PhD, as Senior Vice President of Research and Development (R&D) Strategy; and Donald Treacy, Jr., PhD, as Senior Vice President, Development Operations. The appointments further strengthen Maxwell’s management team, bringing industry-leading leadership to support the company’s clinical R&D strategy and operations. This press release features multimedia. View the full release here: Beth Burnside, PhD, Senior Vice President of Research and Development Strategy (Photo: Business Wire) “As Maxwell looks to accelerate the progress of its CLAROMER™ drug platform, we are pleased to welcome Tony, Beth, and Don,” said Maxwell Biosciences CEO and Co-Founder, Joshua McClure. “I am confident that the appointments of these industry veterans – who bring extensive depth and breadth of expertise – will further strengthen our world-class team and position us to more rapidly realize the benefits of our platform, offering a new approach to safely and effectively inactivate viruses, bacteria and fungi to benefit patients across a variety of infections.” Tony Verco, MD, MBA has over 25 years of international biotech and pharmaceutical experience, with a specific focus on early-stage drug development, operational oversight, and pharmacovigilance of clinical trial programs. He most recently was the owner of Shelton Clinical Research Consultants, LLC, and previously held leadership roles at Medwell Capital Corp. (formerly BioMS Medical Corp.), Endpoint Research and AstraZeneca, UK. He also held Unit Physician and Principal Investigator roles at AstraZeneca, UK, and Leicester Clinical Research Center. He holds a Bachelor of Medicine, Bachelor of Surgery (MD) from the University of the Witwatersrand in South Africa, a Masters in Business Administration (MBA) from New York Institute of Technology in the U.S., and a Diploma in Anaesthetics (DA) from the Royal College of Medicine in South Africa. Over the past 30 years, Beth Burnside, PhD, has led teams across drug development and delivery, enhanced drug absorption, regulatory affairs, quality and corporate compliance, and intellectual property strategy. She has served as lead inventor or co-inventor on more than 34 issued U.S. patents and numerous related international patents, including developing several pharmaceutical products such as Adderall XR®, Intuniv®, and MOXATAG®. Prior to joining Maxwell, she held executive roles with Lowery Creek Consulting, LLC, QRxPharma, MiddleBrook Pharmaceuticals, Inc. (formerly Advancis Corporation), and Shire Pharmaceuticals. She holds a PhD in Physical Organic Chemistry and an MS in Organic Chemistry, both from Drexel University, and a BS in Chemistry and Mathematics from Muhlenberg College. Donald Treacy, Jr., PhD, brings 30 years of experience across the biotech and pharmaceutical industry, with diverse expertise across research, product development and manufacturing, and regulatory affairs. He most recently was the CEO of Magothy Consulting Group, LLC, and previously held the role of Senior Vice President of Development and Manufacturing Operations at MiddleBrook Pharmaceuticals, Inc. (formerly Advancis Corporation), and Senior Director of Analytical Sciences at Shire Pharmaceuticals. He is the named inventor on over 30 issued U.S. and international patents in novel drug delivery, solid dosage form development and formulation performance, and has authored numerous research publications and presentations on accelerator mass spectrometry, high performance liquid chromatography, and novel drug delivery systems. He holds a PhD in Analytical and Nuclear Chemistry from the University of Maryland, and a BA in Chemistry from Roanoke College. About Maxwell Founded in 2016, Maxwell Biosciences is a preclinical drug platform company which develops biomimetic therapeutics – synthetic compounds that mimic and improve upon biomolecules. Inspired by nature, these low-molecular weight compounds are created by Maxwell’s exclusive first-in-class, CLAROMER™ brand drug platform and have been shown to be effective in destroying viruses, bacteria, fungi and some cancers, while safely avoiding healthy cells. These drug candidates have been shown to be well-tolerated in human tissues in vitro, and in animal studies. The compounds imitate key components of the immune system, humanity’s greatest asset in fighting disease. Maxwell’s technology is protected by granted patents and is led by a world-class team of experienced life science executives. To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com, or follow us on Twitter and LinkedIn.